Platelets News and Research

RSS

Miniature 3D bone marrow model could lead to personalized treatment for blood platelet disorders

A new miniature 3D model of human bone marrow has been described today in the open-access eLife journal.

1 Jun 2021

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Even as a host of vaccines have been rolled out to counter the coronavirus disease 2019 (COVID-19) pandemic, some serious adverse effects have been reported, in the form of thrombocytopenia. A new study in the journal Vaccine reports the results of an evaluation of reported cases of this condition, using data from the Vaccine Adverse Event Reporting System (VAERS).

24 May 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

Blocking TGFβ1 could improve hematopoiesis in AML patients, indicates study

Bone marrow failure due to acute myeloid leukemia (AML) is a significant factor behind the disease's high rate of morbidity and mortality. Previous studies in mice suggest that AML cells inhibit healthy hematopoietic (blood) stem and progenitor cells (HSPC).

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

Study confirms rare blood clotting risk linked to ChAdOx1-S vaccine - benefits still outweigh risks

New research published in BMJ confirmed evidence of blood clotting finding a small risk after receiving one Oxford-AstraZeneca ChAdOx1-S severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.

12 May 2021

Severe COVID-19 linked to genetic clotting predisposition

Thus, the need to stratify the risk of severe or critical disease in patients presenting with SARS-CoV-2 infection remains a crying necessity. A new preprint research paper posted to the medRxiv server discusses the relationship between severe disease and pre-existing susceptibility to clots and other diseases of the cardiovascular system.

11 May 2021

Researchers identify mechanism of platelet hyperactivation in COVID-19 patients

A recent study conducted at the University of Pennsylvania and the Children’s Hospital of Philadelphia, USA, has revealed the mechanism of platelet hyperactivation in critically ill coronavirus disease 2019 (COVID-19) patients.

4 May 2021

New NCCN patient guidelines on anemia and neutropenia published

The National Comprehensive Cancer Network announced today the publication of new NCCN Guidelines for Patients: Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the NCCN Foundation and endorsed by The Leukemia and Lymphoma Society (LLS).

3 May 2021

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Last Friday, the Centers for Disease Control and Prevention and the U.S. Food & Drug Administration lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S.

29 Apr 2021

Purified exosomal product accelerates wound healing in preclinical models

Difficult-to-treat, chronic wounds in preclinical models healed with normal scar-free skin after treatment with an acellular product discovered at Mayo Clinic.

28 Apr 2021

FDA, CDC lift recommended pause on the use of Janssen COVID-19 vaccine in the U.S.

Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

23 Apr 2021

Researchers examine if a naturally occurring protein can be used to prevent sight loss from glaucoma

Researchers funded by Fight for Sight, in partnership with The Spectacle Makers’ Charity and Glaucoma UK, are investigating if a naturally occuring protein in the body can be used to prevent sight loss from glaucoma.

22 Apr 2021

Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks

A recent study by researchers at the University of British Columbia (B.C.) shows that the benefits of continuing the COVID-19 vaccine of front-line workers with the AstraZeneca vaccine outweigh the increased risk of prothrombotic thrombocytopenia.

19 Apr 2021

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Leukemias are debilitating cancers of the hematopoietic or blood-forming cells of the bone marrow. Now, researchers at Tokyo Medical and Dental University describe an ingenious strategy against chronic myelomonocytic leukemia (CMML) wherein an antibody-drug conjugate (ADC) comprising a cytotoxic drug payload linked to an antibody that selectively targets specific cell lines effectively blocks malignant cell proliferation at source.

16 Apr 2021

Aged bone marrow niche restrains function of rejuvenated HSCs, shows study

When leukemia strikes an older person, it is in part due to the aging of his or her hematopoietic stem cells (HSCs).

13 Apr 2021

New fluorescent probe can differentiate between B and T lymphocytes

Human blood contains several different components, including plasma, red blood cells (RBCs), white blood cells (WBCs), and platelets. Among these, WBCs are divided into numerous subcategories each with unique functions and characteristics, such as lymphocytes, monocytes, neutrophils, and others.

13 Apr 2021

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.

12 Apr 2021

GACVS COVID-19 reviews rare cases of blood clots following AstraZeneca COVID-19 vaccination

The COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) has reviewed reports of rare cases of blood clots with low platelets following vaccination with the AstraZeneca COVID-19 vaccine (including Covishield) since their onset a few weeks ago.